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Fluoroquinolone (FQ)-resistant extraintestinal pathogenic Escherichia coli (FQr ExPEC) strains from phylogenetic group B2 are
undergoing epidemic spread. Isolates belonging to phylogenetic group B2 are generally more virulent than other E. coli isolates;
therefore, resistance to FQs among group B2 isolates is concerning. Although clonal expansion of sequence type 131 (ST131) is a
major factor, the contribution of additional clonal groups has not been quantified. Group B2 FQr ExPEC isolates from humans
(n 250) and dogs (n 12) in Australia were screened for ST131, a recently recognized and rapidly emerging multidrug-resis-
tant and virulent clonal group that is important in both human and companion animal medicine. Non-ST131 isolates underwent
virulence genotyping, PCR-based O typing, partial multilocus sequence typing (MLST), pulsed-field gel electrophoresis (PFGE),
and FQ resistance mechanism analysis. Of 49 non-ST131 isolates (45 human, 4 canine), 49% (24 human, 2 canine) represented
O-type O75 and exhibited conserved virulence genotypes (F10 papA allele, iha, fimH, sat, vat, fyuA, iutA, kpsMII, usp, ompT,
malX, K1/K5 capsule) andMLST allele profiles corresponding with clonal complex CC14. Two clusters, each containing canine
and human isolates, were identified by PFGE (differentiated by K1 and K5 capsules). Australian FQr O75 isolates exhibited com-
monality with an historical FQ-susceptible O75 urosepsis isolate (also CC14). The isolation from humans and dogs of highly
similar FQr derivatives of the classic O75:K1/K5 (CC14) ExPEC lineage suggests recent acquisition of FQ resistance and potential
cross-host-species transfer. This lineage should be targeted with ST131 in future epidemiological investigations of FQr ExPEC.
Infections caused by extraintestinal pathogenic Escherichia coli(ExPEC) are very common among humans and dogs. ExPEC
strains isolated from both host species, particularly those belong-
ing to the more virulent phylogenetic group B2, have been shown
to possess pathotypic and phylogenetic similarities (18, 24).
Treatment of ExPEC infections has become increasingly prob-
lematic due to the emergence and spread of clonally related mul-
tidrug-resistant (MDR) strains (12, 15, 32, 37). In particular, se-
quence type 131 (ST131), a newly recognized ExPEC clonal group
from phylogenetic group B2, has shown recent and rapid global
dissemination among humans (15, 25, 35). Multiple reports have
documented the emergence of ST131 also in companion animals,
including both as gastrointestinal carriage in healthy dogs (16)
and as a cause of extraintestinal infection (8, 31, 33). ST131 strains
typically possess awide array of extraintestinal virulence genes and
exhibit resistance to multiple antimicrobial agents of various
classes, including fluoroquinolones and, frequently, extended-
spectrum cephalosporins (30, 35).
Previously, among 262 group B2 fluoroquinolone-resistant
(FQr) E. coli isolates from extraintestinal infections in humans
and companion animals from the east coast of Australia, we
found that ST131 accounted for 206 (82%) of 250 human iso-
lates and 8 (69%) of 12 companion animal isolates (32). Here,
to search for additional broad-host-range multiresistant clonal
groups other than ST131, we assessed the 49 remaining non-
ST131 group B2 isolates (45 from humans, 4 from dogs) for
clonal structure, virulence genotypes, and evidence of interspe-
cies transmission.
MATERIALS AND METHODS
Bacterial isolates. In our previous study (32), 262 (250 human, 12 canine)
phylogenetic group B2 FQr E. coli isolates were identified by PCR-based
phylotyping among 702 FQr ExPEC clinical isolates obtained from hu-
mans and dogs in eastern Australia (2). The human isolates were obtained
from two Brisbane private pathology laboratories processing samples
from both hospitals (approximately 80 to 85% of submissions) and com-
munity clinics (approximately 15 to 20% of submissions) between Octo-
ber 2007 and October 2008, and the canine isolates were from four veter-
inary pathology laboratories (serving Brisbane, Sydney, and Melbourne)
processing samples from both community clinics and referral hospitals
between October 2007 and October 2009. Group B2 isolates underwent
PCR-based screening for ST131-specific single-nucleotide polymor-
phisms (SNPs) in mdh and gyrB (15); this identified 213 (205 human, 8
canine) isolates as ST131 and 49 (45 human, 4 canine) as non-ST131 (32).
For comparative purposes, four historical fluoroquinolone-susceptible
phylogenetic group B2 O75 blood isolates from humans with urosepsis
(strains 2H19, PM3, V21, and V8) (19) were included.
O typing and further isolate selection. As O types may be a primary
indicator of clonal association, the 49 FQr non-ST131 group B2 isolates
underwent PCR-based O typing to detect 13 known clonal group- and/or
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sepsis-associated rfb variants (O1, O2, O4, O6, O11, O12, O15, O16, O18,
O25a, O25b, O75, andO157) (3, 4). Twenty-six isolates belonging to O75
(i.e., 24 human and 2 canine isolates) were further characterized, as de-
tailed below. In addition, the remaining 2 non-O75 canine isolates and 6
(30%; randomly selected) of the 21 remaining non-O75 human isolates
were also characterized to determine the level of diversity among the non-
O75 isolates.
Susceptibility testing. The 34 selected isolates underwent disk diffu-
sion testing for susceptibility to 19 antimicrobials, including amikacin,
amoxicillin-clavulanic acid, ampicillin, aztreonam, cefepime, cefoxitin,
ceftazidime, cephalothin, chloramphenicol, ciprofloxacin, enrofloxacin,
gentamicin, imipenem, nitrofurantoin, piperacillin, piperacillin-tazobac-
tam, streptomycin, tetracycline, and trimethoprim-sulfamethoxazole (5,
6). Resistance was defined as nonsusceptibility (i.e., resistance or interme-
diate susceptibility) according to standardized interpretative criteria (5,
6). An isolate’s resistance scorewas the number of antimicrobials towhich
the isolate demonstrated resistance, whereas the resistance profile was the
combination of antimicrobials to which the isolate exhibited resistance.
Resistance profiles were examined to provide information about the ex-
tent and specific patterns of resistance, plus provide some (albeit weak)
indication regarding clonality.
Virulence gene profiling and lactose fermentation determination.
Isolates were screened for 52 ExPEC-associated virulence marker genes
and their variants using established multiplex PCR assays (11, 13, 19, 21).
Here, the term “virulence genes” is used to include proven or putative
virulence-associated genes and associated variants. Virulence scores re-
flected the total number of virulence genes identified, with adjustment for
multiple detection of certain operons (i.e., pap, sfa-foc, and kps). Virulence
genotype similarity between isolates was calculated as the number of vir-
ulence genes concordantly detected in both isolates divided by the total
number of virulence genes detected in either isolate. Virulence profiles
provide some indication of the organism’s virulence potential (as re-
flected in the total number and particular combination of constituent
virulence genes), and they may have associations with specific clonal
groups and thus provide another marker for clonality independently of
their virulence implications. Lactose fermentation was determined by
plating on MacConkey agar.
PFGE. For a more discriminating assessment of within- and across-
species genomic commonality, the 34 selected Australian isolates and the
4 historical isolates underwent comparative pulsed-field gel electropho-
resis (PFGE) analysis according to a standardized protocol (34). Dice
coefficient-based similarity dendrograms were constructed within
BioNumerics software (Bio-Rad) according to the unweighted-pair group
method with arithmetic mean. Isolates were considered to represent the
same pulsotype if they exhibited94% profile similarity, which approx-
imates to a3-band difference (39).
MLST. To classify the study isolates as to clonal group and to enable
interlaboratory comparisons, the 34 selected Australian isolates under-
went partial multilocus sequence typing (MLST) (for fumC, gyrB, and
recA) according to the Achtman system (http://mlst.ucc.ie/mlst/dbs
/Ecoli). Subsequently, to give a full 7-locus MLST, the remaining 4 loci
were analyzed for 9 of these isolates (4 canine, 5 human). The 4 historical
O75 isolates also underwent full 7-locus MLST.
Determination ofMICs.Twenty-three randomly selected non-ST131
FQr isolates, including half of the O75 isolates (13 human and 2 canine)
and one-third of the non-O75 isolates (6 human and 2 canine), under-
went broth microdilution fluoroquinolone MIC determination with en-
rofloxacin, ciprofloxacin, moxifloxacin, and pradofloxacin (40), a new
veterinary fluoroquinolone. Methods and interpretive criteria were as
specified by the Clinical and Laboratory Standards Institute (CLSI) (5, 6)
for all antibiotics except pradofloxacin, for which the epidemiological
breakpoint of 2 g/ml was used (9).
Detection of fluoroquinolone resistance genes. For the same 23 iso-
lates, fluoroquinolone resistance-associated chromosomal gene muta-
tions were determined by PCR amplification and pyrosequencing of the
quinolone resistance-determining regions (QRDRs) within gyrA and
parC (31). Screening for the plasmid-mediated quinolone resistance
(PMQR) genes qnrA, qnrB, qnrS, and qepA was performed by multiplex
PCR (31). A second PCR was done to identify isolates containing the
aac(6=)-Ib-cr variant (31). The degree of homogeneity (or lack thereof) in
the fluoroquinolone resistance genesmay also aid as amarker for clonality
and may be used to indicate divergence among FQr isolates.
Efflux pump activity testing. Two methods were used to indicate the
level of efflux pump activity on the 23 representative isolates: MIC testing
in the presence of an efflux pump inhibitor and an organic solvent toler-
ance test. For the former, susceptibility to 4 fluoroquinolones (enrofloxa-
cin, ciprofloxacin, moxifloxacin, and pradofloxacin) was determined in
duplicate in the presence of 64 g/ml of L-phenylalanyl-arginyl--naph-
thylamide (PAN; P 4157; Sigma) using broth microdilution (5, 6). Or-
ganic solvent tolerance was assessed as described previously (31).
Statistical methods. Comparisons of proportions were tested using
Fisher’s exact test. Resistance and virulence scores were compared using
Mann-Whitney U tests. Analyses were performed using Stata (version
10.0) software (Statacorp, College Station, TX). Diversity of resistance
types and virulence types was compared using Simpson’s index of diver-
sity (1-D) (38). The criterion for assuming statistical significance was a P
value of0.05.
RESULTS
O typing and susceptibility testing. Of the 49 non-ST131 FQr
group B2 clinical isolates (45 human, 4 canine), approximately
half (n 26; 24 human, 2 canine) represented O-type O75. All 26
O75 isolates were confirmed to be FQr by disc diffusion and broth
microdilution MIC determination. Coresistance to non-FQ anti-
microbial agents was common among the 26 O75 isolates, with
75% of isolates exhibiting resistance to ampicillin (96%), pip-
eracillin (96%), streptomycin (96%), trimethoprim-sulfame-
thoxazole (88%), and tetracycline (85%). Resistance to gentami-
cin (58%), cephalothin (8%), and amoxicillin-clavulanic acid
(4%) was less prevalent. In contrast, all 26 O75 isolates were sus-
ceptible to amikacin, aztreonam, cefepime, cefoxitin, ceftazidime,
chloramphenicol, imipenem, nitrofurantoin, and piperacillin-ta-
zobactam. Resistance scores ranged from 3 to 10 (median, 8).
Among the 26 isolates, 8 different resistance profiles were demon-
strated (Table 1).
Among the non-O75 isolates examined (n  8; 2 canine, 6
human), 1 canine isolate showed intermediate susceptibility to
both enrofloxacin and ciprofloxacin by disk diffusion, whereas
MIC testing indicated susceptibility at the breakpoint for both
fluoroquinolones; therefore, this isolate was excluded from fur-
ther study. Data were therefore collated for six randomly selected
non-O75 human isolates and one non-O75 canine isolate. All
seven isolates were resistant to ampicillin, the only non-FQ agent
to which a75% resistance prevalence was detected among these
isolates. Other less prevalent resistances included cephalothin
(71%). piperacillin (57%), tetracycline (57%), trimethoprim-sul-
famethoxazole (57%), amoxicillin-clavulanic acid (43%), cefoxi-
tin (29%), gentamicin (29%), streptomycin (29%), and chloram-
phenicol (14%). All seven non-O75 isolates were susceptible to
amikacin, aztreonam, cefepime, ceftazidime, imipenem, nitrofu-
rantoin, and piperacillin-tazobactam. Resistance scores ranged
from 5 to 8 (median, 7; versus O75 isolates, P 0.25). Compared
with the O75 isolates (1-D 0.71), resistance profiles were more
diverse among the seven non-O75 isolates (1-D  1), each of
which had a unique profile (Table 1).
Virulence genotypes and lactose fermentation.Among the 26
O75 isolates, 17 different virulence markers were detected overall,
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with individual isolates having a median virulence score of 12
(range, 11 to 13). Virulence genotypes were highly similar, with
pairwise similarity values ranging from 96.5% to 100%. The O75
isolates’ consensus virulence genotype included the F10 papA al-
lele (P fimbria structural subunit variant), iha (adhesin-sidero-
phore receptor), fimH (type 1 fimbriae), sat (secreted autotrans-
porter toxin), vat (vacuolating autotransporter toxin), fyuA
(yersiniabactin receptor), iutA (aerobactin receptor), kpsMII
(group 2 capsule), usp (uropathogenic specific protein), ompT
(outer membrane protease), and malX (pathogenicity island
marker), with variation limited to presence/absence of the K1 and
K5 group 2 capsule variants (Table 2). None of the detected viru-
lence markers differed in prevalence between human and com-
panion animal O75 isolates.
In contrast, among the non-O75 isolates, 41 (79%) of the 52
virulence genes were detected, with isolates having a median vir-
ulence score of 13 (range, 4 to 20). Virulence profiles were much
more diverse among the non-O75 isolates than among the O75
isolates, with pairwise virulence genotype similarity values rang-
ing from as low as 60% to no higher than 94%.Comparedwith the
O75 isolates (1-D  0.61), resistance profiles were more diverse
among the seven non-O75 isolates (1-D 1), each of which had a
unique profile.
All 26 Australian O75 isolates were lactose nonfermenters. In
contrast, all 7 non-O75 comparison isolates fermented lactose
(P 0.001).
Pulsed-field gel electrophoresis. In a dendrogram based on
XbaI PFGE profiles for the 26 analyzed AustralianO75 isolates (24
human, 2 canine), all but 2 of the isolates fell within two distinct
clusters which exhibited 90% within-cluster profile similarity
and82%between-cluster profile similarity (Fig. 1) with no tem-
poral clustering. Supporting the clusters’ biological validity was
their internal homogeneity for the presence of either the K1 (clus-
ter I, pulsotype 1297) or K5 (cluster II, pulsotype 1298) capsule
variants for the Australian isolates. The outlier O75 isolates exhib-
ited81% similarity to the two main clusters. Notably, both ca-
nine O75 isolates (one K1, one K5) fell into the cluster corre-
sponding with the isolate’s K type; each was 91% similar to
human isolates within that cluster.
Multilocus sequence typing. All 26 Australian O75 study iso-
lates that underwent MLST possessed the same 3-locus haplotype
(fumC14, gyrB10, recA10), implying commonality at the ST level.
In contrast, the 7 non-O75 isolates (6 human, 1 canine) exhibited
7 distinct allele combinations, evidence of disparate ST back-
grounds. All 7 of the Australian O75 isolates (5 human, 2 canine)
that underwent 7-locus MLST belonged to ST1193, which is
within clonal complex CC14, differing from ST14 by only 1 nu-
cleotide in icd.
Fluoroquinolone resistance characteristics. Among the 23
FQr isolates that underwent FQ MIC determination (15 O75, 8
non-O75), MICs were lowest for pradofloxacin (median, 4 g/
ml), in themidrange for ciprofloxacin andmoxifloxacin (median,
16g/ml), and highest for enrofloxacin (median, 32g/ml), with
no apparent differences between the O75 and non-O75 isolates.
All but one of theO75 isolates exhibited identical fluoroquinolone
resistance-associated mutations in the QRDR of gyrA and parC,
i.e., gyrA S83L (TCG to TTG) and D87N (GAC to AAC) and parC
S80I (AGC to AGT), plus a silent gyrA mutation V85V (GTT to
GTC), compared to the sequence of wild-type E. coli. The sole
exceptionwas human isolate QU108, in which the parC PCR frag-
ment could not be sequenced. In contrast, the non-O75 isolates
exhibited diverse mutations in gyrA and parC (not shown).
Additional FQ resistance mechanisms, qnrA, qnrB, qnrS, qepA,
and aac(6=)-1b-cr variant, were not detected in any isolate. Like-
wise, although all 23 isolates exhibited a 4-fold decrease in the
MICs of enrofloxacin, moxifloxacin, and pradofloxacin in the
presence of the efflux pump inhibitor PAN, only 1 O75 isolate
(QU108, human) and 4 of 7 non-O75 isolates (3 human and 1
canine) exhibited various degrees of organic solvent tolerance.
Historical O75 isolates. According to 7-locus MLST, the 4
historical O75 urosepsis isolates represented ST14 (strain 2H19),
ST550 (strains V8 and V21), and ST576 (strain PM3), all of which
TABLE 1 Resistance profiles of 26 O75 isolates and 7 non-O75 isolates from humans and dogs
Resistance profilea
No. of isolates with
profilePenicillins Other beta-lactams FQs Misc. Antifolate
AMP PIP AMC AZ KF FOX CAZ CIP ENR GM C T S SXT
O75
(n 26)
Non-O75
(n 7)
              12 0
              8 1
              1 0
              1 0
              1 0
              1 0
              1 0
              1 0
              0 1
              0 1
              0 1
              0 1
              0 1
              0 1
33 29 4 1 7 2 1 33 33 17 1 26 26 26 26 7
a Misc., miscellaneous; AMP, ampicillin; AMC, amoxicillin-clavulanic acid; AZ, aztreonam; KF, cephalothin; CAZ, ceftazidime; FOX, cefoxitin; C, chloramphenicol; CIP,
ciprofloxacin; ENR, enrofloxacin; GM, gentamicin; PIP, piperacillin; T, tetracycline; SXT, trimethoprim-sulfamethoxazole; S, streptomycin;, resistant;, sensitive.
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are within CC14. The virulence genotypes of the historical FQ-
susceptible O75/CC14 isolates were highly similar to those of the
present FQ-resistant Australian isolates (Table 2). They included
all the virulence genes found in the Australian O75 isolates; addi-
tionally, V21 contained clbB and clbN, 2H19 contained a complete
copy of the pap operon plus traT, and PM3 contained clbB and
clbN, traT, and afa-dra. PFGE showed 85% profile similarity
between reference isolate 2H19 and theAustralianO75:K1 isolates
(cluster I, pulsotype 1297) (Fig. 1).
DISCUSSION
The recent worldwide emergence of FQr phylogenetic group B2
ExPEC has occurred primarily through clonal expansion of E. coli
ST131 (30, 31, 35). This study sought to determine if non-ST131
FQr phylogenetic group B2 isolates from extraintestinal infections
in both humans and dogs also exhibit clonality and whether
across-host-species commonality could be detected. We docu-
ment the apparent emergence of FQr variants of an O75-associ-
ated clonal group (ST1193, CC14), accounting for approximately
10% of a large collection of phylogenetic group B2 FQr E. coli
isolates from Australia. Although the vast majority (81%) of this
collection was previously determined to represent ST131 (31, 32),
here we show that approximately half of the remaining FQr iso-
lates represent this newly recognized, FQr O75-associated ST1193
(CC14) clonal group.
Our findings support four main conclusions regarding the
O75/ST1193 isolates. First, the O75/ST1193 isolates account for
half of the non-ST131 FQr group B2 population in this collection
of E. coli isolates from eastern Australia. Second, these isolates are
highly clonal, as indicated by both PFGE and MLST and their
possession of a relatively homogeneous repertoire of virulence
genes, resistance profiles, and FQ resistance mechanisms. Third,
although this conclusion is based on a small number of isolates,
Australian O75/ST1193 isolates from both humans and dogs are
indistinguishable, i.e., are likely to be derived from a recent com-
mon ancestor and to have undergone anthroponotic-zoonotic
transfer. Lastly, several isolates exhibited close genetic similarity to
an historical FQ-susceptible O75 urosepsis isolate from the
United States, indicating that rather than being a recently emerged
clonal group, the O75 isolates identified in the current study are
likely to be descendants of a more long-standing clonal lineage
that has more recently acquired FQr mechanisms. Further studies
that aim to retrospectively examine FQ-sensitive strain collections
for their clonal structure are needed to confirm this conclusion.
Escherichia coli serotype O75 has long been associated with
urinary tract infection (UTI) and sepsis in humans (7, 29), viru-
lence-associated phylogenetic group B2 (28), Dr-binding (for-
merly termed “O75X”) adhesins (27), and ampicillin resistance
(27). However, it has not historically been associated with FQ
resistance, which could be an important phenotype contributing
to recent clonal expansion. Although the extent of clonality within
serogroup O75 has not been broadly determined, some studies
evaluating the virulence gene repertoire or using methods such as
ribotyping point to a strongly clonal population structure (26, 28).
However, to the best of our knowledge, previous studies have not
simultaneously investigated clonality, virulence, and the occur-
rence of FQ resistance among O75 isolates.
Our finding that FQr E. coliO75 strains are not host specific to
humans is consistent with both the previous evidence that canine
UTI isolates commonly belong to human UPEC-associated sero-
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groups, including O75 (22), and the frequent isolation of another
successful FQr clonal group, i.e., ST131, from both humans and
dogs (16, 31). It appears that fluoroquinolone resistance among
phylogenetic group B2 isolates, at least in Australia, is emerging
mainly by expansion of two resistant clonal groups—primarily
ST131, as previously described (31), and ST1193, as described
here—rather than by arising repeatedly by independent muta-
tions in diverse genetic backgrounds.
Historically, FQr extraintestinal infection isolates have tended
to represent the less virulent phylogenetic groups D and A (10,
36). In contrast, phylogenetic group B2 E. coli isolates, which tend
to possess an enhanced array of virulence genes, typically have
been more susceptible to antimicrobials, including FQs (14). In
conflict with this classic paradigm, two clonal groups within
group B2, i.e., ST131 and theO75-associated ST1193 clonal group
described here, possess an extensive virulence gene repertoire (15,
25), together with a multidrug resistance phenotype. Thus, this
O75 clonal group and ST131 demonstrate that resistance and en-
hanced virulence can no longer be regarded as mutually exclusive
within E. coli. Concurrence of resistance and virulence within ep-
idemic ExPEC clonal groups was demonstrated previously by the
phylogenetic group D-derived clonal groups CC69 (clonal group
A; O11/O17/O73/O77:K52:H18) andO15:K52:H1, albeit with re-
sistance to trimethoprim-sulfamethoxazole rather than fluoro-
quinolones (1, 17, 20). A corollary of this finding is that group
B2-derived clonal groups clearly can no longer be presumed to be
susceptible to clinically important antimicrobials, aswas true until
recently.
The O75 ST1193 clonal group isolates possessed nearly identi-
cal virulence genotypes that included the F10 papA allele, iha,
fimH, sat, vat, fyuA, iutA, kpsMII, usp, ompT, andmalX, differing
only for presence of the K1 or K5 group 2 capsule variants. Al-
though according to virulence genotype and PFGE profile our
Australian O75 isolates closely resembled an FQ-susceptible O75
urosepsis isolate from Seattle,WA, from the 1980s (isolate 2H19),
they lacked traT and most pap operon genes (19), which, in con-
trast, were present in strain 2H19. Moreover, both 2H19 and the
Australian O75 isolates lacked clbB and clbN, which were present
in the other historical O75 urosepsis isolates. On a broad scale,
most O75 isolates appear to belong to a prevalent clonal complex
(CC14) that has been widely geographically distributed for de-
cades, if not longer (23). Certainly, phylogenetic group B2 and
serogroup O75 have been associated with urinary tract infection
and sepsis for over half a century, and the virulence traits seen in
FIG 1 Dendrogram of XbaI pulsed-field gel electrophoresis profiles of 38 phylogenetic group B2 Escherichia coli isolates, 34 human O75 isolates, 4 canine O75
isolates, 6 human non-O75 isolates, 2 canine non-O75 isolates, and 4 historical O75 isolates.
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our Australian O75 isolates are known to be broadly disseminated
among O75 strains (7, 28, 29). Interestingly, all isolates belonging
to the O75/ST1193 clonal group were lactose nonfermenters,
which may have implications regarding detection in a clinical mi-
crobiology setting.
PFGE analysis resolved two main subgroups (i.e., clusters)
among theO75 isolates, one characterized by theK1 capsule (clus-
ter I) and the other (which included historical isolate 2H19) by the
K5 capsule (cluster II). Within each cluster, the constituent hu-
man and canine isolates were intermingled, without evident spe-
cies-specific segregation. Although the number of companion an-
imal isolates is low, our identification of highly genetically similar
human and veterinary E. coli O75 isolates, which coincides with
our previous demonstration of clonality among human and ca-
nine ST131 isolates, suggests the potential for transmission be-
tween humans and their pets and/or vice versa.
The homogeneity of the Australian FQr O75 ST1193 isolates
suggests recent dissemination of successful new FQr clonal vari-
ants among both humans and dogs. In contrast, a lesser degree of
homogeneity exists among the historical O75 isolates, further ev-
idence that the Australian O75/ST1193 isolates recently emerged
and spread from a common ancestor, most likely within the lin-
eage represented by the historical O75 isolate 2H19. This is sup-
ported by the identical pattern of a double nonsynonymous mu-
tation (S83L [TCG to TTG] and D87N [GAC to AAC]) plus a
single silent mutation (V85V [GTT to GTC]) in gyrA and a single
nonsynonymous mutation in parC (S80I [AGC to AGT]) in all
Australian FQrO75 isolates compared to the varied gyrA and parC
mutations observed in the non-O75 group.
In conclusion, we have documented a high prevalence of clon-
ally related FQr serogroup O75 ExPEC isolates from ST1193
among humans and dogs in Australia. Further studies of current
and historical FQr isolate collections are required to determine if
this is a local or broader (e.g., global) phenomenon and to pin-
point in time the development of FQ resistance among O75 iso-
lates. Furthermore, there is a global need for strategic surveillance
and control schemes for FQr extraintestinal E. coli with high viru-
lence potential, particularly given the emergence and spread of
multiresistant group B-derived clonal groups such as ST131 and,
now, ST1193 (CC14).
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